SomnoMedASX:SOM +0.94%50 Interest Coverage is 13.06 as of Dec. 2025, which is 145% above its 10-year median of 5.33. GuruFocus rates ASX:SOM with a GF Score™ of 50/100 and a GF Value™ of A$0.45 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 468 Medical Devices & Instruments companies, SomnoMed ranks worse than 68.59% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. SomnoMed's
Operating Income
for the
six
months ended in Dec. 2025 was A$2.8 Mil. SomnoMed's Interest Expense for the
six
months ended in Dec. 2025 was A$-0.2 Mil.
SomnoMed's interest coverage for the quarter that ended in Dec. 2025 was 13.06.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for SomnoMed's Interest Coverage or its related term are showing as below:
ASX:SOM'
s Interest Coverage Range Over the Past 10 Years
Min: 4.48 Med: 5.33 Max: 6.99
Current: 6.99
ASX:SOM's Interest Coverage is ranked worse than 68.59% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 15.71
vs ASX:SOM: 6.99
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
SomnoMed Interest Coverage Related Terms
SomnoMed Interest Coverage Historical Data
* Premium members only.
The historical data trend for SomnoMed's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:SOM vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, SomnoMed's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SomnoMed Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's Interest Coverage distribution charts can be found below:
* The bar in red indicates where SomnoMed's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed (ASX:SOM) has a Interest Coverage of 13.06 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on SomnoMed and its competitors. This is 145% above median its historical median of 5.33. Over the past decade, SomnoMed's Interest Coverage has ranged from 4.48 to 6.99. According to the industry distribution chart, SomnoMed ranks #321 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 68.6%.
Is SomnoMed's Interest Coverage too high?
SomnoMed's current Interest Coverage of 13.06 is 145% above median its 10-year median of 5.33. Over the past 10 years, this metric has ranged from a low of 4.48 to a high of 6.99. The Medical Devices & Instruments industry median Interest Coverage is 15.71. SomnoMed's value of 13.06 is 16.9% below this industry median. Based on the distribution chart, SomnoMed ranks #321 out of 468 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, SomnoMed has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #321 out of 468 companies for Interest Coverage. This places SomnoMed in the lower half of its industry. The industry median Interest Coverage is 15.71. SomnoMed's value of 13.06 is 16.9% below this benchmark. Historically, SomnoMed's own Interest Coverage has ranged from 4.48 to 6.99 over the past decade. While the company's 10-year median is 5.33 vs. the industry median of 15.71, SomnoMed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.71, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SomnoMed's current Interest Coverage of 13.06 is 16.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on SomnoMed and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SomnoMed's current Interest Coverage is 13.06, which is 145% above median its own 10-year median of 5.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (ASX:SOM) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.45, compared to a current price of A$0.54 — trading 18.9% above its estimated fair value. The current Interest Coverage is 13.06, which is 145% above median its 10-year median of 5.33 and 16.9% below the Medical Devices & Instruments industry median of 15.71. SomnoMed's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For SomnoMed (ASX:SOM), the current Interest Coverage is 13.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SomnoMed (ASX:SOM) Overvalued in 2026?
Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued.
The current stock price of A$0.54 is trading 18.9% above its estimated GF Value™ of A$0.45.
GuruFocus considers SomnoMed to be Modestly Overvalued.
Key valuation signals for ASX:SOM:
Interest Coverage: 13.06 (145% above median its 10-year median of 5.33)
GF Value™: A$0.45 vs. price of A$0.54 (18.9% above fair value)
Industry Position: 16.9% below the Medical Devices & Instruments median (#321 of 468)
No single metric tells the full story. See the ASX:SOM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
50GF Score
Get the complete analysis for ASX:SOM
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SOM has been successfully added to your 
